FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3195616002> ?p ?o ?g. }

• W3195616002 abstract "Multiple myeloma (MM) is a heterogeneous disease, with an estimated 34 920 newly diagnosed cases in the United States in 2021 according to the American Cancer Society. Long-term survival has improved with the development of proteasome inhibitors (PI), immunomodulatory drugs (IMiDs), and monoclonal antibodies with overall survival (OS) exceeding 10 years for patients with standard-risk MM. However, outcomes for the 25%-45% of patients characterized as high-risk are poor, with a median OS of 18–24 months.1, 2 Relapse after autologous stem cell transplantation (ASCT) is inevitable with or without lenalidomide (len) maintenance.2 Immune dysfunction in MM is, in part, due to functionally defective dendritic cells, increased TH17 cells, myeloid devoid suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) in the BM and peripheral blood. Since T-cell clonal expansion after ASCT has been associated with improved clinical outcomes,3 we hypothesized that by incorporating a checkpoint inhibitor into post-ASCT consolidation, it will reinvigorate a T-cell inflamed phenotype to target residual MM. We used len which has shown to enhance T cell and NK cell effector anti-MM responses, reducing PD-L1 expression on MM cells4 and combine it with pembrolizumab, a PD-1 inhibitor. We used the combination of pembrolizumab (pembro) plus len and dexamethasone (dex) which has previously shown an acceptable safety profile and improved efficacy in previous studies5 and intended to enroll 58 patients to our an open-label, phase II single-arm trial (NCT02906332). However, all studies evaluating the combination of PD-1 or PDL-1 inhibitors with IMiDs were halted by the FDA on July 3, 2017 due to a higher incidence of immune-related toxicities and deaths in the pembro arm. At the time of the FDA hold, 12 subjects were enrolled. Follow-up was permitted. Study procedures were as follows: Patients were enrolled between days +60 and + 180 following ASCT and received treatment with pembro-len-dex (pembro-rd) for a total of four cycles. The combination included pembro 200 mg IV on day 1; len 25 mg p.o. daily on days 1–14; and dex 40 mg daily at days 1, 8, 15 of a 21-day cycle for a total of two cycles and then an additional two cycles of pembro-rd at the same dose and frequency. After the completion of cycle four, each subject was followed for 30 days. Serious adverse events were collected for 90 days after the end of treatment. Subjects who discontinued treatment for reasons other than disease progression continued post-treatment follow-up. Participants included adult patients with measurable disease and hrMM defined by any of the following: ISS stage 3; del 13q by cytogenetics; FISH with 1q amplification, 1p deletion (del), p53 del, t (4;14), t (14;16), t (14;20), hypodiploidy; or a high-risk gene expression profile score. Patients were excluded if they had progression of disease at time of screening or if there was evidence of organ dysfunction. Minimal Residual Disease (MRD) assessments were performed 30 days after the fourth cycle for those achieving VGPR or better. Peripheral blood samples were analyzed at screening, at cycle two, day 1 of treatment and at long-term follow-up. Cells were processed by Ficoll-Paque Plus (Fisher Scientific) separation. A portion of the cells underwent immune phenotyping by fluorescent-labeled monoclonal antibody (mAb) staining for T-cell subsets. This included mAb purchased from BD Biosciences for: CD3-Alexa Fluor 647 (#557706), CD4-APC-Cy7 (#557871), CD45RO-FITC (#555492), CD25-PerCP-Cy5.5 (#560503), CD127-FITC (#560549), CD8-PE (#555635), CCR7-PC7 (#557648), and matched fluorescent labeled isotype control mAb. The intent-to-treat population consisted of all the enrolled patients who received at least one dose of study drug and was the basis for the analysis of efficacy endpoints. Demographic and clinical variables were summarized using median (IQR) for continuous variables and counts (percentages) for categorical variables. The Kaplan–Meier method was used to determine median PFS and OS, respectively. Responses to treatment by each cycle were descriptively summarized. Both AE and SAEs were tabulated descriptively. For T-cell subset phenotypic analysis, paired continuous data were compared using Mood's median test. A two-sided p < 0.05 was considered statistically significant. Data analysis was performed using R (ver. 4.0.2). Results were as follows: Of the 12 patients, five (41.7%) were ISS 3, six (50%) had a p53 deletion by FISH, three (25%) had 1q21 gain, and two (17%) were considered ultra-high risk with combination of 1q21 gain and 13q deletion by FISH (Table S1). All patients received triplet or quadruplet induction. Five patients (42%) received induction bortezomib-lenalidomide-dex; four (33%) carfilzomib-lenalidomide-dex, two (24.9%) bortezomib-cyclophosphamide-dex and one bortezomib-cyclophosphamide-len-dex. Median follow-up was 50 months. The median PFS from the date of ASCT for all patients with a median follow-up of 50.7 months (range: 6–55.5 months) was 27.7 months (95% CI: 22.6 months - not reached, Figure S1). The PFS rates at 1 and 2-year follow-up was 90.9% and 63.6%, respectively. Overall response rate was 100% at time of best response (Figure S2). The rate of stringent complete remission was 33% at the end of induction and 83.3% at the end of consolidation and 83.3% at the pre-specified 7th follow-up point (a median of 19 months after completion of treatment) (Figure 1). For all patients, over the 2-year follow-up period, 11/12 (91.7%) achieved a complete remission or better, and 10/12 (83.3%) achieved stringent complete remission (Table S2). Of the 11 patients who completed therapy, eight had MRD status assessed and among them, seven (87.5%) were MRD negative by multiparametric flow cytometry with a cut-off value of 10−5. Adverse events (AEs) were monitored at every visit and graded according to the guidelines outlined in the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. All patients had one or more AEs attributed to pem, len or dex. Of the 97 AEs reported, 6.2% were grade 3 and 93.8% were grade 1 or 2. The most common non-hematologic AEs were respiratory (cough) and gastrointestinal (diarrhea and constipation), all grade 1 or 2, while the most common hematologic AE was neutropenia with six occurrences observed among two patients, grade 1–3. Immune-mediated AEs included diarrhea in four patients, fever in one patient, maculopapular rash in one patient, and dyspnea in two patients. All were grade 1 or 2. There was one serious AE, H. influenza pneumonia requiring inpatient admission, which was unrelated to pembrolizumab (Table S3). In comparison to the C1D1 start of the first treatment cycle, the median percent effector memory CD4+ T cells within the CD3 compartment decreased steadily through C4D1 (p = 0.037). The effector memory CD8 compartment in the CD3 population exhibited a small decrease at the time of the second cycle (C2D1) (p = 0.032) and returned to insignificantly increased levels by the third cycle (p = 0.199). The median percentage Memory regulator T cells was not significantly decreasing through the second cycle (C2D1) and third cycle (C3D1) (p = 1.0, p = 0.199, respectively) (Table S4). Our results suggest that PD-1 blockade in combination with len, given as post-ASCT consolidation, was well tolerated and efficacious in 12 hrMM patients with a median PFS of 2.3 years, exceeding So, PFS in hrMM patients without len maintenance from historical controls.6 Immune mediated AEs were only grade 1 or 2 while the one SAE observed was unrelated to pembro. Lymphocyte composition and function after ASCT guided optimal timing of immunotherapy and helped identifying potential markers of relapse. Regulatory T cells (Treg) decline as CD8(+) T cells expand during early lymphocyte recovery after ASCT, markedly reducing the Treg:CD8(+) effector T-cell ratio. These CD8(+) T cells can respond to autologous dendritic cells presenting tumor antigen in vitro as early as day +12 after transplant, becoming antigen-specific cytolytic T-lymphocyte effectors and thereby demonstrating preservation of cellular reactivity. A subpopulation of exhausted/senescent CD8(+) T cells, however, downregulates CD28 and upregulates CD57 and PD-1, characterizing immune impairment and relapse after ASCT. Relapsing patients have higher numbers of these cells at +3 months after transplant, but before detection of clinical disease, indicating their applicability in identifying patients at higher risk of relapse. Thus, PD-1 blockade also revives the proliferation and cytokine secretion of the hyporesponsive, exhausted/senescent CD8(+) T cells in vitro. Collectively, these results identify T-cell exhaustion/senescence as a distinguishing feature of relapse and support early introduction of immunotherapy to stimulate antitumor immunity after ASCT (Table S4). The pembro-rd combination may have an important role as consolidation therapy after ASCT, aiming to achieve a change from an “anergic” to a more “active” immune milieu. This trial provides long-term follow-up of patients with hrMM who have received the combination of checkpoint inhibitors and IMiDS regarding safety and efficacy. While enrollment was limited after the FDA hold, the outcomes were significantly better than historical controls for unmaintained patients would have suggested. The combination of PD1 blockade and IMiDs as a short consolidative regimen offers the possibility of long-term disease control in a population of patients that do not typically achieve this, even with standard maintenance therapies. N.B. has received consultancy fees, honoraria and speakers' bureau fees from Janssen, B.M.S., Takeda, Amgen, Karyopharm, Celgene, and Sanofi. D.S.S. has received consultancy fees, honoraria and speakers' bureau fees from Janssen, BMS, Takeda, Amgen, Karyopharm, Celgene, and Sanofi. D.H.V. has received consultancy fees, honoraria and speakers' bureau fees from Janssen, G.S.K., Karyopharm, Amgen, Takeda. He is also in the Advisory board for Pfizer and owns stock from Abbvie, Amgen, Biogen, Gilead, Johnson & Johnson, Lilly. J.R. has received consultancy fees honoraria and speakers' bureau fees from Janssen, Celgene, B.M.S., Karyopharm, Sanofi, X4 pharmaceuticals, Oncopeptides, adaptive biotechnologies, Secura bio, Astra Zeneca. J.A. is a statistical consultant of the company “KeifeRx”. E.G.P., J.Z., A.L.P., P.A., K.I., M.B., R.K., M.D., L.M., R.F., S.W., S.R. have nothing relevant to disclose. Study conception and design: David S. Siegel and Noa Biran. Provision, collection, and assembly of data: All authors contributed to data collection. Data analysis and interpretation: All authors had access to the data and participated in data collection and interpretation. Manuscript writing, editing and approval: All authors. Supported in part by a research grant from the Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp & Dohme Corp. Table S1 Baseline characteristics (N = 12) . Table S2: Best overall response to treatment. Table S3: Weighted reported adverse events (All AEs presented below are grade 1 or 2 apart the ones marked with “̂” that are grade 3). Table S4: T cell subset phenotypic analysis. Figure S1 Progression-free survival Kaplan–Meier curve Figure S2: Overall survival Kaplan–Meier curve. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article." @default.
• W3195616002 created "2021-08-30" @default.
• W3195616002 creator A5004466299 @default.
• W3195616002 creator A5019999670 @default.
• W3195616002 creator A5020522068 @default.
• W3195616002 creator A5023752321 @default.
• W3195616002 creator A5030703994 @default.
• W3195616002 creator A5033124739 @default.
• W3195616002 creator A5033513950 @default.
• W3195616002 creator A5034381928 @default.
• W3195616002 creator A5045239840 @default.
• W3195616002 creator A5045451441 @default.
• W3195616002 creator A5051483089 @default.
• W3195616002 creator A5061423277 @default.
• W3195616002 creator A5069315060 @default.
• W3195616002 creator A5069732469 @default.
• W3195616002 creator A5075392356 @default.
• W3195616002 creator A5079671192 @default.
• W3195616002 creator A5090941234 @default.
• W3195616002 date "2021-09-17" @default.
• W3195616002 modified "2023-10-14" @default.
• W3195616002 title "Pembrolizumab, Lenalidomide and Dexamethasone Post Autologous Transplant in Patients with High‐Risk Multiple Myeloma" @default.
• W3195616002 cites W1955732360 @default.
• W3195616002 cites W2117672959 @default.
• W3195616002 cites W2505446618 @default.
• W3195616002 cites W2750997727 @default.
• W3195616002 cites W2955183528 @default.
• W3195616002 cites W2962324833 @default.
• W3195616002 doi "https://doi.org/10.1002/ajh.26333" @default.
• W3195616002 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34435374" @default.
• W3195616002 hasPublicationYear "2021" @default.
• W3195616002 type Work @default.
• W3195616002 sameAs 3195616002 @default.
• W3195616002 citedByCount "2" @default.
• W3195616002 countsByYear W31956160022022 @default.
• W3195616002 countsByYear W31956160022023 @default.
• W3195616002 crossrefType "journal-article" @default.
• W3195616002 hasAuthorship W3195616002A5004466299 @default.
• W3195616002 hasAuthorship W3195616002A5019999670 @default.
• W3195616002 hasAuthorship W3195616002A5020522068 @default.
• W3195616002 hasAuthorship W3195616002A5023752321 @default.
• W3195616002 hasAuthorship W3195616002A5030703994 @default.
• W3195616002 hasAuthorship W3195616002A5033124739 @default.
• W3195616002 hasAuthorship W3195616002A5033513950 @default.
• W3195616002 hasAuthorship W3195616002A5034381928 @default.
• W3195616002 hasAuthorship W3195616002A5045239840 @default.
• W3195616002 hasAuthorship W3195616002A5045451441 @default.
• W3195616002 hasAuthorship W3195616002A5051483089 @default.
• W3195616002 hasAuthorship W3195616002A5061423277 @default.
• W3195616002 hasAuthorship W3195616002A5069315060 @default.
• W3195616002 hasAuthorship W3195616002A5069732469 @default.
• W3195616002 hasAuthorship W3195616002A5075392356 @default.
• W3195616002 hasAuthorship W3195616002A5079671192 @default.
• W3195616002 hasAuthorship W3195616002A5090941234 @default.
• W3195616002 hasBestOaLocation W31956160021 @default.
• W3195616002 hasConcept C121608353 @default.
• W3195616002 hasConcept C126322002 @default.
• W3195616002 hasConcept C143998085 @default.
• W3195616002 hasConcept C2776063141 @default.
• W3195616002 hasConcept C2776364478 @default.
• W3195616002 hasConcept C2777701055 @default.
• W3195616002 hasConcept C2780057760 @default.
• W3195616002 hasConcept C2780401358 @default.
• W3195616002 hasConcept C71924100 @default.
• W3195616002 hasConceptScore W3195616002C121608353 @default.
• W3195616002 hasConceptScore W3195616002C126322002 @default.
• W3195616002 hasConceptScore W3195616002C143998085 @default.
• W3195616002 hasConceptScore W3195616002C2776063141 @default.
• W3195616002 hasConceptScore W3195616002C2776364478 @default.
• W3195616002 hasConceptScore W3195616002C2777701055 @default.
• W3195616002 hasConceptScore W3195616002C2780057760 @default.
• W3195616002 hasConceptScore W3195616002C2780401358 @default.
• W3195616002 hasConceptScore W3195616002C71924100 @default.
• W3195616002 hasFunder F4320332932 @default.
• W3195616002 hasIssue "11" @default.
• W3195616002 hasLocation W31956160021 @default.
• W3195616002 hasLocation W31956160022 @default.
• W3195616002 hasOpenAccess W3195616002 @default.
• W3195616002 hasPrimaryLocation W31956160021 @default.
• W3195616002 hasRelatedWork W2003305967 @default.
• W3195616002 hasRelatedWork W2091675597 @default.
• W3195616002 hasRelatedWork W2118465399 @default.
• W3195616002 hasRelatedWork W2147528312 @default.
• W3195616002 hasRelatedWork W2192430028 @default.
• W3195616002 hasRelatedWork W2208379272 @default.
• W3195616002 hasRelatedWork W2430400806 @default.
• W3195616002 hasRelatedWork W2474837444 @default.
• W3195616002 hasRelatedWork W3195616002 @default.
• W3195616002 hasRelatedWork W3217566318 @default.
• W3195616002 hasVolume "96" @default.
• W3195616002 isParatext "false" @default.
• W3195616002 isRetracted "false" @default.
• W3195616002 magId "3195616002" @default.
• W3195616002 workType "article" @default.